 |
|
|
| |
THE PHARMACOKINETICS (PK) OF DOVATO (50 MG DOLUTEGRAVIR [DTG]/
300 MG LAMIVUDINE [3TC]) FIXED-DOSE COMBINATION IN HIV-INFECTED PATIENTS
|
| |
| |
International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs Virtual Meeting, September 28-30, 2020
Reported by Jules Levin
Teodora Pene Dumitrescu,1 Jonathan Wright,2 Mounir Ait-Khaled,3 Brian Wynne,4 Kimberly Adkison,4 Hardik Chandasana,5 Rajendra Singh6
1GlaxoSmithKline, Upper Providence, PA, USA; 2GlaxoSmithKline, Stockley Park, UK; 3ViiV Healthcare, Brentford, UK; 4ViiV Healthcare, Research Triangle Park, NC, USA; 5GlaxoSmithKline, Collegeville, PA, USA; 6GlaxoSmithKline, King of Prussia, PA, USA
|
| |
|
|
|
|
|
